Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003386
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama +59 locations
Conditions: Ovarian Cancer
Register for Updates
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
NCT00003184
Completed
RATIONALE: Vaccines made from breast cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccines made from breast cancer cells in treating women with metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2013
Locations: Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland, Oregon
Conditions: Breast Cancer
Register for Updates
Higher Dose Intradermal H5 Vaccine
NCT00439335
Completed
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults. The study will look at the safety of the injections, how the body reacts, and what the body's immune response does when the vaccine is given in the muscle versus in the skin. The study will look at 226 healthy volunteers, ages 18-49 years old. Study procedures will include getting 2 doses of vaccine 28 days apart, physical exams, follow-up clinic visits to c... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/28/2013
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Influenza
Register for Updates
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
NCT00104845
Completed
RATIONALE: Vaccines made from DNA may make the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Melanoma (Skin)
Register for Updates
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
NCT01224262
Completed
This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2013
Locations: Accelovance - Melbourne, Melbourne, Florida
Conditions: Influenza
Register for Updates
Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults
NCT00249106
Completed
The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/08/2013
Locations: Rockefeller University Hospital, New York, New York +1 locations
Conditions: HIV Infection
Register for Updates
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004029
Completed
Phase I trial to study the effectiveness of vaccine therapy in treating patients with metastatic prostate cancer. Vaccines may make the body build an immune response to kill tumor cells.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/08/2013
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Prostate Cancer
Register for Updates
Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
NCT01215734
Completed
Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not be significantly different from adult stem cell transplant recipients receiving standard dose (SD) TIV. * Specific Aim 1: To compare safety profile of high dose trivalent inactivated influenza vaccine to standard dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplant recipients. Hyp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2013
Locations: Vanderbilt-Ingram Cancer Center, Clinical Trials Information Program, Nashville, Tennessee
Conditions: Adult Stem Cell Hematopoetic Transplant
Register for Updates
Tetravalent Chimeric Dengue Vaccine Trial
NCT01110551
Completed
The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus. Live attenuated means that while this vaccine contains 4 live dengue viruses the viruses have been attenuated (weakened) so as not to cause dengue disease in people. Dengue virus is spread to people by mosquitoes and can cause sickness and even death. Seventy-two subjects between the ages of 18-45 years old will be enrolled in this... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/31/2013
Locations: Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri
Conditions: Dengue
Register for Updates
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT00028496
Completed
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2013
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
NCT00005039
Terminated
Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT00030693
Terminated
Randomized phase I trial to compare the effectiveness of two different vaccines given directly into the tumor in treating patients who have metastatic solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. It is not yet known which vaccine may be more effective in treating metastatic solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Mount Sinai Medical Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates